IMCR Immunocore Holdings plc
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1671927 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.1%
TTM net income YoY-9.9%
TTM EPS YoY-10.3%
Revenue 3-yr CAGR25.9%
Net income 3-yr CAGR—
Margins
Gross margin98.9%
Operating margin-6.8%
Net margin-7.5%
FCF margin-4.2%
EBITDA margin-5.9%
Returns
ROE-7.9%
ROA-2.9%
ROIC (approx.)—
Asset turnover0.38x
Leverage & solvency
Liabilities / assets62.8%
Debt / equity0.00x
Current ratio4.62x
Interest coverage-2.37x
Cash quality & payout
Operating cash flow / net income0.32x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $102.22M | $115.93M | $106.68M | $104.48M | $103.69M | $97.96M | $93.88M | $84.05M |
| Cost of revenue | $676,000 | $1.09M | $434,000 | $2.70M | $513,000 | $1.04M | $831,000 | $330,000 |
| Gross profit | $101.55M | $114.84M | $106.24M | $101.78M | $103.18M | $96.92M | $93.05M | $83.72M |
| R&D expense | $74.70M | $73.94M | $61.11M | $78.82M | $70.57M | $69.01M | $56.47M | $60.85M |
| SG&A expense | $40.45M | $43.89M | $37.85M | $42.65M | $39.78M | $42.79M | $40.20M | $42.32M |
| Operating income | -$13.61M | -$3.00M | $7.28M | -$19.69M | -$7.17M | -$14.88M | -$3.62M | -$19.45M |
| Interest expense | $3.06M | $3.06M | $3.05M | $3.05M | $3.04M | $3.04M | $3.02M | $7.04M |
| Pretax income | -$14.07M | -$514,000 | $13.27M | -$15.79M | $304,000 | -$9.69M | $6.08M | -$24.82M |
| Income tax | $153,000 | $294,000 | $301,000 | $14.27M | $481,000 | $606,000 | $1.06M | -$1.05M |
| Net income | -$14.22M | -$808,000 | $12.97M | -$30.06M | -$177,000 | -$10.30M | $5.02M | -$23.77M |
| EBITDA | -$12.50M | -$1.97M | $8.23M | -$19.02M | -$6.37M | -$14.10M | -$2.76M | -$18.29M |
| EPS (basic) | -0.28 | -0.02 | 0.26 | — | 0.00 | -0.20 | 0.10 | — |
| EPS (diluted) | -0.28 | -0.02 | 0.25 | — | 0.00 | -0.20 | 0.10 | — |
| Weighted avg. shares (diluted) | 51.56M | 50.97M | 52.93M | — | 50.40M | 50.29M | 51.95M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $512.25M | $484.92M | $452.68M | $467.71M | $498.41M | $487.93M | $476.85M | $455.73M |
| Short-term investments | $389.05M | $395.29M | $392.22M | $396.44M | $393.94M | $394.88M | $360.19M | $364.64M |
| Receivables | — | — | — | — | — | — | — | $63.01M |
| Inventory | $7.47M | $7.79M | $8.25M | $6.74M | $5.66M | $5.46M | $6.80M | $5.45M |
| Current assets | $1.06B | $1.05B | $1.00B | $996.74M | $1.02B | $1.00B | $948.62M | $929.86M |
| PP&E, net | $14.05M | $12.86M | $12.13M | $11.46M | $9.43M | $9.55M | $9.77M | $10.09M |
| Total assets | $1.13B | $1.12B | $1.07B | $1.07B | $1.10B | $1.08B | $1.03B | $1.01B |
| Current liabilities | $229.62M | $235.20M | $240.11M | $246.70M | $170.35M | $170.08M | $149.16M | $212.18M |
| Total liabilities | $709.53M | $699.62M | $678.42M | $686.24M | $705.94M | $693.91M | $649.53M | $648.79M |
| Shareholders' equity | $419.71M | $419.80M | $393.67M | $381.03M | $396.56M | $388.48M | $378.48M | $360.72M |
| Shares outstanding | 51.64M | 51.48M | 50.83M | 50.69M | 50.47M | 50.37M | 50.18M | 50.06M |
| Cash flow statement | ||||||||
| Operating cash flow | $20.09M | $15.93M | -$13.78M | -$32.66M | -$4.46M | $25.96M | $435,000 | -$13.95M |
| Capital expenditure | $2.35M | $786,000 | $1.78M | $2.88M | $748,000 | $414,000 | $298,000 | $3.58M |
| Free cash flow | $17.74M | $15.14M | -$15.56M | -$35.53M | -$5.20M | $25.55M | $137,000 | -$17.54M |
| Investing cash flow | $4.65M | -$786,000 | $4.22M | -$880,000 | $5.25M | -$30.41M | $9.70M | -$3.54M |
| Financing cash flow | $3.75M | $16.48M | $656,000 | $4.28M | $1.87M | $3.67M | $2.55M | -$51.51M |
| Depreciation & amortization | $1.11M | $1.03M | $948,000 | $668,000 | $798,000 | $780,000 | $854,000 | $1.16M |
| Stock-based compensation | $9.73M | $9.40M | $6.30M | $8.34M | $9.84M | $10.03M | $9.49M | $8.67M |
Free plan shows the latest 8 periods; Pro shows all 20 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.